• M Halpenny, S Lakshmi, A O'Donnell, S O'Callaghan-Enright, D O'Connell, and G Shorten.
• Department of Anesthesia, Cork University Hospital, Wilton, Ireland.
• J. Cardiothorac. Vasc. Anesth. 2001 Feb 1; 15 (1): 72-6.

ObjectiveTo quantify the effects of fenoldopam, 0.1 microg/kg/min, on left internal mammary artery (LIMA) and saphenous vein blood flow after coronary anastomosis.DesignProspective, randomized, double-blind, placebo-controlled trial.SettingUniversity teaching hospital, single institution.ParticipantsThirty-one American Society of Anesthesiologists III patients undergoing elective coronary revascularization.InterventionsA perivascular ultrasonic flow probe (Linton Instrumentation, Norfolk, UK) was placed around the LIMA and saphenous vein graft after coronary anastomosis.Measurements And Main ResultsImmediately before and at 5-minute intervals for 15 minutes after starting the infusion, blood flow was measured in the LIMA and one saphenous vein graft using a transit time ultrasonic flow probe. Heart rate, blood pressure, and central venous pressure were documented at these time points. Administration of fenoldopam, 0.1 microg/kg/min, did not alter heart rate or blood pressure. A small, nonsignificant increase in LIMA blood flow occurred during the 15-minute study period (30 +/- 12 to 35 +/- 10 mL/min) in patients who received fenoldopam. No significant changes occurred in the placebo group.ConclusionsThe findings indicate that fenoldopam, 0.1 microg/kg/min, did not influence coronary conduit blood flow to a clinically significant extent. The small increase in LIMA blood flow may be of greater importance in high-risk patients or in the prevention of coronary arterial spasm.

21 keywords...

hide…